KLOW (80 mg Vial) Dosage Protocol

KLOW (80 mg Vial) Dosage Protocol

Quickstart Highlights

KLOW (80 mg) is a multi‑peptide research blend most commonly labeled as GHK‑Cu 50 mg + BPC‑157 10 mg + TB‑500 10 mg + KPV 10 mg per vial. There is no universally accepted clinical dosing schedule for this blend; this page focuses on precise measurement and reconstitution so researchers can design study‑specific protocols.

  • Reconstitute to a practical concentration and measure with insulin syringes
  • At 3 mL reconstitution (max vial capacity), 1 unit (0.01 mL) ≈ 266.7 mcg of total mixture
  • Per‑unit component equivalence (3 mL): GHK‑Cu ≈ 166.7 mcg; BPC‑157 ≈ 33.3 mcg; TB‑500 ≈ 33.3 mcg; KPV ≈ 33.3 mcg
  • Store lyophilized vials in a cool, dry place; refrigerate after mixing (2–8 °C)

Research use only. Not for human consumption. Not medical advice.

KLOW 80 mg Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and syringe-based measurement (no standardized dosing protocol exists for this blend)

Measurement & Reconstitution (3 mL = ~26,667 mcg/mL mixture)

Injection Option Dosage (mixture & per‑component) Units (mL)
Option A ~2.667 mg mixture per injection → GHK‑Cu ~1.667 mg; BPC‑157 ~0.333 mg (333 mcg); TB‑500 ~0.333 mg (333 mcg); KPV ~0.333 mg (333 mcg) 10 units (0.10 mL)
Option B ~4.000 mg mixture per injection → GHK‑Cu ~2.500 mg; BPC‑157 ~0.500 mg (500 mcg); TB‑500 ~0.500 mg (500 mcg); KPV ~0.500 mg (500 mcg) 15 units (0.15 mL)
Option C ~5.333 mg mixture per injection → GHK‑Cu ~3.333 mg; BPC‑157 ~0.667 mg (667 mcg); TB‑500 ~0.667 mg (667 mcg); KPV ~0.667 mg (667 mcg) 20 units (0.20 mL)
Option D ~8.000 mg mixture per injection → GHK‑Cu ~5.000 mg; BPC‑157 ~1.000 mg; TB‑500 ~1.000 mg; KPV ~1.000 mg 30 units (0.30 mL)

Reconstitute with 3 mL of bacteriostatic water to maximize measurability on 100‑unit insulin syringes (aiming for ≥10 units per injection). If your planned volume would fall below ~10 units at 3 mL dilution, consider smaller insulin syringes (30–50 unit) for precision.

  1. Draw 3.0 mL of bacteriostatic water into a sterile syringe.
  2. Inject slowly along the vial wall to minimize foaming; allow powder to dissolve.
  3. Gently swirl—avoid vigorous shaking.
  4. Store reconstituted solution at 2–8 °C, protected from light. Do not freeze. Use within ~30 days.
Note: This guide standardizes measurement only. There is no established clinical dosing schedule for KLOW. Content is for lawful laboratory research and educational purposes only.

Protocol Overview

A concise summary of reconstitution and per‑unit conversions for this multi‑peptide research blend.

  • Blend (typical label): GHK‑Cu 50 mg + BPC‑157 10 mg + TB‑500 10 mg + KPV 10 mg per 80 mg vial
  • Reconstitution: 3 mL (max vial capacity) → ~26,667 mcg/mL mixture
  • Per‑Unit Equivalence (0.01 mL): ~266.7 mcg mixture; GHK‑Cu ~166.7 mcg; BPC‑157 ~33.3 mcg; TB‑500 ~33.3 mcg; KPV ~33.3 mcg
  • Measurement Options: Common increments shown (10u/15u/20u/30u) to keep volumes ≥10 units for accuracy
  • Scheduling: Define frequency and total exposure by study design, model, and IACUC/ethics approvals

Dosing Protocol

This page does not prescribe a fixed dosing schedule. Use the conversion table to select volumes appropriate for your protocol endpoints.

  • Example increments (per injection): 10u ≈ 2.667 mg mixture; 15u ≈ 4.000 mg; 20u ≈ 5.333 mg
  • Frequency: Set per study (e.g., daily, every other day, or weekly), informed by endpoint measures and component literature
  • Assay Planning: Record both units and calculated mg/mcg per component for reproducibility
  • Injection Route: Typically subcutaneous for solution studies unless model dictates otherwise
  • Compliance: Research use only; adhere to local/institutional regulations

Storage Instructions

Proper storage supports peptide integrity.

  • Lyophilized: Cool, dry, light‑protected storage
  • Reconstituted: Refrigerate at 2–8 °C; avoid repeated freeze–thaw
  • Use Within: ~30 days after mixing (laboratory best practice)
  • Handling: Aseptic technique; label vial with date, diluent, and concentration

Supplies Needed

Plan supplies based on your study’s injection frequency and chosen volume.

  • Peptide Vials (Product ID: 17302):
    Capacity per vial @ 3 mL:
    • 10u per injection → ~30 injections/vial
    • 15u per injection → ~20 injections/vial
    • 20u per injection → ~15 injections/vial
    • 30u per injection → ~10 injections/vial
    Example planning: 2 injections/week at 20u ≈ ~7–8 weeks per vial; adjust to your schedule.
  • Insulin Syringes: 100‑unit; consider 30–50‑unit syringes for finer measurements
  • Bacteriostatic Water: 1× 30 mL
  • Alcohol Swabs: 1 box
KLOW 80 mg Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Important Notes

Practical tips to enhance safety and data quality.

  • Use sterile technique; rotate injection sites; document lot numbers and dates
  • Pre‑calculate component mg/mcg delivered per injection for transparent reporting
  • Monitor the model for adverse responses; halt per IACUC/ethics protocol if concerns arise
  • Ensure chain‑of‑custody and cold‑chain integrity for reconstituted solutions

How This Works

KLOW combines four peptides studied across complementary pathways relevant to tissue modeling and inflammation.

  • GHK‑Cu: Copper‑binding tripeptide associated with ECM remodeling, collagen/elastin synthesis, and pro‑repair gene expression; evaluated in in vitro, animal, and dermatologic studies.
  • TB‑500 (Thymosin β4 fragment): Linked to cell migration (actin dynamics), angiogenesis, and wound repair; Tβ4 formulations (e.g., RGN‑137) have been investigated clinically for dermal healing and corneal injury.
  • BPC‑157: Gastric‑derived pentadecapeptide reported to modulate angiogenesis and NO signaling with cytoprotective effects in numerous animal models; limited early human safety/PK data.
  • KPV (α‑MSH 11‑13): C‑terminal tripeptide of α‑MSH with anti‑inflammatory activity via melanocortin‑related pathways and PepT1‑mediated uptake; studied in colitis and mucosal healing models.

Potential Research Signals & Considerations

Preclinical literature suggests roles in ECM remodeling, angiogenesis, and inflammation modulation; translational significance remains under active investigation.

  • Observed signals in models: increased collagen deposition, enhanced cell migration and re‑epithelialization, reduced inflammatory markers
  • Potential adverse events (general to peptide studies): injection‑site reactions, edema, headache or fatigue; long‑term safety of combinations is not established
  • Follow institutional and regulatory guidance; verify each component against applicable competition or compliance rules

Study Design Factors

Simple controls that can strengthen outcomes.

  • Standardize timing (circadian) and route of administration
  • Control diet, hydration, and physical activity across cohorts where relevant
  • Predefine endpoints (histology, biomechanical testing, cytokine panels) and blinding

Injection Technique

General laboratory guidance for subcutaneous administration.

  • Disinfect stopper and site with alcohol swabs; use new sterile needle/syringe each time
  • Pinch subcutaneous tissue; insert at 45–90°; inject slowly
  • Rotate sites (abdomen, thigh) and document volumes/locations

Important Note

This guide is for educational and research purposes only. It does not provide medical advice and is not a treatment recommendation.

References


    • Maquart et al., FEBS Lett.
      – GHK‑Cu stimulates collagen synthesis in fibroblasts
      View Source

    • Pickart & Margolina, J Aging Res Clin Pract / Reviews
      – GHK/ GHK‑Cu biology and skin remodeling overview
      View Source

    • Pickart et al., Dermatology/Cosmetics Review
      – Regenerative & protective actions of GHK‑Cu (gene data)
      View Source

    • JAMA Facial Plast. Surg.
      – Topical copper tripeptide complex in CO₂ laser resurfacing patients
      View Source


    • Zhang et al., Front. Pharmacol. (Review)
      – Progress on function & application of Thymosin β4
      View Source

    • Kaur et al., J Invest Dermatol / Reviews
      – Tβ4 as a multi‑functional regenerative peptide
      View Source

    • NCT00832091 – ClinicalTrials.gov
      – Tβ4 (RGN‑137) in venous stasis ulcers (dermal wound trial)
      View Source

    • Sosne et al., Ocul. Surf. / PMC
      – Thymosin β4 as corneal wound‑healing and anti‑inflammatory agent
      View Source


    • Seiwerth et al., Front. Pharmacol. 2021
      – BPC‑157 and wound healing mechanisms (review)
      View Source

    • Šikić et al., Pharmaceuticals 2024
      – Pleiotropic effects and limited early human evidence (review)
      View Source

    • Chang et al., J Appl Physiol. 2011
      – BPC‑157 promotes tendon/ligament healing in rodent models
      View Source

    • NCT02637284 – ClinicalTrials.gov
      – Phase I safety & PK of BPC‑157 in healthy volunteers
      View Source

    • Lee et al., PubMed 2025
      – Pilot: IV BPC‑157 up to 20 mg in two adults (tolerability)
      View Source

    • Vasireddi et al., Orthop. Sports Med. 2025
      – Systematic review of BPC‑157 in musculoskeletal models
      View Source


    • Catania et al., Br J Pharmacol. (Review)
      – α‑MSH peptides as anti‑inflammatory agents; KPV as minimal active sequence
      View Source

    • Dalmasso et al., Gastroenterology
      – PepT1‑mediated uptake of KPV reduces colitis
      View Source

    • Kannengiesser et al., Inflamm Bowel Dis.
      – KPV anti‑inflammatory effects in murine colitis models
      View Source

    • Xiao et al., Mol Ther. 2017
      – HA‑targeted nanoparticles delivering KPV for ulcerative colitis
      View Source


  • Vendor Label – KLOW (80 mg) Spec
    – GHK‑Cu 50 mg / BPC‑157 10 mg / TB‑500 10 mg / KPV 10 mg per vial
    View Source

  • Vendor Label – KLOW (80 mg) Spec
    – Blend listing across suppliers (GHK‑Cu/BPC‑157/TB‑500/KPV)
    View Source